

CITATION REPORT

List of articles citing

Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis

DOI: 10.1016/0002-9343(94)90151-1
American Journal of Medicine, 1994, 96, 254-9.

Source: <https://exaly.com/paper-pdf/25350548/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
274	Systemic lupus erythematosus. 1995 , 97, 79-94		45
273	[The heart and antiphospholipid antibodies. Personal experience and review of the literature]. 1996 , 17, 46-57		3
272	Biochemical characterization of ADP-ribose polymer metabolism in SLE. <i>Lupus</i> , 1996 , 5, 14-21	2.6	115
271	The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review. <i>Lupus</i> , 1996 , 5, 59-64	2.6	25
270	Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. <i>Lupus</i> , 1996 , 5, 16-22	2.6	143
269	Systemic lupus erythematosus. 1996 , 34, 20-3		
268	Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. 1996 , 25, 191-3		137
267	Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. 1997 , 56, 374-7		87
266	Accelerated atherosclerosis and coronary disease in SLE. <i>Lupus</i> , 1997 , 6, 572-7	2.6	32
265	Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. <i>Lupus</i> , 1997 , 6, 533-9	2.6	215
264	Pathogenesis and treatment of the antiphospholipid antibody syndrome. 1997 , 81, 151-77		74
263	Prevention and treatment of adverse effects of corticosteroids in systemic lupus erythematosus. 1998 , 12, 495-510		18
262	Dermatologic lupus: Hopkins Lupus Cohort. 1998 , 17, 219-27		19
261	Hydroxychloroquine: past, present, future. <i>Lupus</i> , 1998 , 7, 65-7	2.6	30
260	Coronary artery bypass grafting in patients with systemic lupus erythematosus. 1999 , 15, 697-701		10
259	The heart in systemic lupus erythematosus. 1999 , 24, 1-56		31
258	Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. 1999 , 42, 338-46		417

257	Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. 1999 , 42, 1785-96		215
256	Management of lipid disorders. 1999 , 25, 507-20		2
255	Cardiac involvement in systemic lupus erythematosus. 1999 , 74, 275-84		197
254	Damage in systemic lupus erythematosus and its association with corticosteroids. 2000 , 43, 1801-8		352
253	Treatment of the antiphospholipid antibody syndrome: progress in the last five years?. 2000 , 2, 256-61		12
252	Atherosclerosis and systemic lupus erythematosus. 2000 , 2, 19-23		27
251	Accelerated atheroma in lupus--background. <i>Lupus</i> , 2000 , 9, 161-5	2.6	41
250	Hydroxychloroquine has no significant effect on lipids and apolipoproteins in Chinese systemic lupus erythematosus patients with mild or inactive disease. <i>Lupus</i> , 2000 , 9, 413-6	2.6	29
249	Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. <i>Lupus</i> , 2000 , 9, 170-5	2.6	173
248	Hopkins Lupus Cohort. 1999 update. 2000 , 26, 199-213, v		91
247	Premature atherosclerosis in systemic lupus erythematosus. 2000 , 26, 257-78		101
246	Coronary artery disease in systemic lupus erythematosus: A review of the literature. 2001 , 30, 436-43		59
245	Transesophageal and transthoracic echocardiography and Doppler-examinations in systemic lupus erythematosus. 2001 , 30, 275-81		44
244	What will treatment of autoimmune diseases entail in 2010?. 2001 , 23, 187-92		
243	Atherosclerosis et connectivites. 2001 , 68, 931-943		0
242	Systemic lupus erythematosus in three ethnic groups. IX. Differences in damage accrual. 2001 , 44, 2797-806		208
241	Elevated blood viscosity in systemic lupus erythematosus. 2001 , 31, 52-7		11
240	Atherosclerosis and connective tissue diseases. 2001 , 68, 564-75		29

239	Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients. <i>Lupus</i> , 2001 , 10, 359-63	2.6	30
238	Antimalarials--the TealTadvance in lupus. <i>Lupus</i> , 2001 , 10, 385-7	2.6	55
237	SLE in three ethnic groups XIII. the TweightedTcriteria as predictors of damage. <i>Lupus</i> , 2002 , 11, 329-31	2.6	18
236	Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit. <i>Lupus</i> , 2002 , 11, 71-81	2.6	53
235	Coronary electron beam computed tomography in 13 patients with systemic lupus erythematosus and two or more cardiovascular risk factors. 2002 , 8, 316-21		6
234	The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas--a randomized trial. 2002 , 55, 209-19		120
233	[Systemic lupus erythematosus and cardiovascular disease]. 2002 , 119, 699-706		2
232	How does one assess and monitor patients with systemic lupus erythematosus in daily clinical practice?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2002 , 16, 181-94	5.3	5
231	Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?. 2002 , 46, 862-73		493
230	Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. 2003 , 48, 3159-67		271
229	Tackling ischaemic heart disease in rheumatoid arthritis. 2003 , 42, 607-13		107
228	Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. 2003 , 349, 2399-406		1084
227	Cardiovascular risk in systemic lupus erythematosus--evidence of increased oxidative stress and dyslipidaemia. 2003 , 42, 758-62		61
226	Mesangial lupus nephritis in Chinese is associated with a high rate of transformation to higher grade nephritis. <i>Lupus</i> , 2003 , 12, 665-71	2.6	20
225	Cardiac Involvement in Systemic Lupus Erythematosus. 2003 , 1, 145-161		1
224	Estudo de perfusã miocfídica e cineangiocoronariografia em pacientes com lpus eritematoso sistfhnico. 2004 , 44, 259-267		
223	The prevalence of dyslipoproteinemia in Thai patients with systemic lupus erythematosus. <i>Lupus</i> , 2004 , 13, 961-8	2.6	7
222	CARDIOVASCULAR SYSTEMIC LUPUS ERYTHEMATOSUS. 2004 , 913-942		1

221	Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature. 2004 , 33, 336-51		94
220	Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2004 , 3, 423-53	13.6	130
219	Coronary artery aneurysm with systemic lupus erythematosus. 2004 , 52, 379-82		8
218	Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. 2004 , 50, 3947-57		246
217	CARDIOVASCULAR SYSTEMIC LUPUS ERYTHEMATOSUS. 2004 , 913-942		1
216	Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2004 ,	13.6	
215	[Systemic lupus erythematosus and accelerated atheromatosis]. 2004 , 123, 704-6		1
214	Coronary and valvular syndromes and antiphospholipid antibodies. 2004 , 114, 501-7		39
213	Prevalence of physician-diagnosed systemic lupus erythematosus in the United States: results from the third national health and nutrition examination survey. 2004 , 13, 713-8		72
212	Atherosclerosis and systemic lupus erythematosus. 2004 , 12, 267-75		23
211	Laboratory Features of Cutaneous Lupus Erythematosus. 2005 , 311-322		3
210	[Accelerated atherosclerosis in rheumatic systemic diseases as an example of systemic lupus erythematosus--what is the consequence?]. 2005 , 64, 229-38		2
209	Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005 , 19, 823-38	5.3	48
208	Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. 2005 , 52, 1473-80		261
207	Lupus in Baltimore: evidence-based 'clinical pearls' from the Hopkins Lupus Cohort. <i>Lupus</i> , 2005 , 14, 970-86		39
206	Disease modification and cardiovascular risk reduction: two sides of the same coin?. 2005 , 44, 1473-82		59
205	The management of pediatric systemic lupus erythematosus. 2005 , 1, 82-92		9
204	Coronary artery disease in patients with systemic lupus erythematosus. 2005 , 1, 55-9; quiz 60		9

203	Not only...but also T factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. 2005 , 44, 1492-502		217
202	Cutaneous Lupus Erythematosus. 2005 ,		11
201	Premature atherosclerosis and acute coronary syndrome in systemic lupus erythematosus. <i>American Journal of Emergency Medicine</i> , 2005 , 23, 696-703	2.9	10
200	Cardiac involvement in systemic lupus erythematosus. <i>Lupus</i> , 2005 , 14, 683-6	2.6	230
199	[Antimalarials: an update in rheumatic diseases]. 2006 , 2, 190-201		8
198	Lupus and Cardiovascular Disease: The Facts. <i>Lupus</i> , 2006 , 15, 3-10	2.6	13
197	Increased aortic pulse wave velocity in middle aged women with systemic lupus erythematosus. <i>Lupus</i> , 2006 , 15, 644-50	2.6	38
196	[Is it necessary to monitor blood hydroxychloroquine concentrations in patients with systemic lupus erythematosus?]. 2006 , 27, 655-7		2
195	Artrite reumática e doenças cardiovasculares. 2006 , 46, 60-66		5
194	The cardiovascular manifestations of rheumatic diseases. 2006 , 18, 135-40		9
193	Cardiac Manifestations in Antiphospholipid Syndrome. 2006 , 41-52		4
192	Traditional risk factor assessment does not capture the extent of cardiovascular risk in systemic lupus erythematosus. 2006 , 36, 237-43		36
191	Prevention of cardiovascular disease in patients with rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2006 , 20, 741-56	5.3	5
190	Premature Atherosclerosis in Systemic Lupus Erythematosus: Pathogenesis and Therapeutic Considerations. 2006 , 8, 48-54		2
189	The complex nature of the interaction between disease activity and therapy on the lipid profile in patients with pediatric systemic lupus erythematosus. 2006 , 54, 1283-90		19
188	Mechanisms of dyslipoproteinemias in systemic lupus erythematosus. 2006 , 13, 203-8		53
187	Antiphospholipid (Hughes) syndrome and atheroma. <i>Lupus</i> , 2006 , 15, 55-58	2.6	5
186	The influence of other drugs on coronary heart disease (CHD) risk in systemic lupus erythematosus. <i>Lupus</i> , 2006 , 15, 23-26	2.6	1

185	Hughes Syndrome. 2006 ,		5
184	Antimalarials in systemic lupus erythematosus: benefits beyond disease activity. 2006 , 1, 225-233		5
183	Therapy of cutaneous lupus erythematosus. 2006 , 1, 105-120		2
182	Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. <i>Lupus</i> , 2006 , 15, 577-83	2.6	279
181	Microcirculatory hemodynamics and endothelial dysfunction in systemic lupus erythematosus. 2006 , 26, 2281-7		43
180	Haematopoietic and endothelial progenitor cells are deficient in quiescent systemic lupus erythematosus. 2007 , 66, 865-70		78
179	African-American and Hispanic ethnicities, renal involvement and obesity predispose to hypertension in systemic lupus erythematosus: results from LUMINA, a multiethnic cohort (LUMINAXLV). 2007 , 66, 618-22		36
178	Management of dyslipidemia in children and adolescents with systemic lupus erythematosus. <i>Lupus</i> , 2007 , 16, 618-26	2.6	35
177	The second hit: comorbidities in systemic lupus erythematosus. 2007 , 2, 497-506		2
176	Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients. <i>Lupus</i> , 2007 , 16, 273-8	2.6	44
175	Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus. 2007 , 56, 1384-96		93
174	Athfome et lupus fythfmateux systhique. 2007 , 74, 1235-1239		
173	Systemic lupus erythematosus: modern strategies for management: a moving target. <i>Best Practice and Research in Clinical Rheumatology</i> , 2007 , 21, 971-87	5.3	9
172	Atheroma and systemic lupus erythematosus. 2007 , 74, 566-70		18
171	Accelerated atherosclerosis in rheumatoid arthritis. 2007 , 1108, 349-58		74
170	The role of preventive cardiology in systemic lupus erythematosus. 2007 , 9, 125-30		14
169	Prevalence and factors associated with dyslipoproteinemias in Brazilian systemic lupus erythematosus patients. 2008 , 28, 323-7		18
168	Lupus nephritis and Raynaud's phenomenon are significant risk factors for vascular thrombosis in SLE patients with positive antiphospholipid antibodies. 2008 , 27, 345-51		29

167	Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus?. 2008 , 59, 169-75		76
166	Drugs to Treat Systemic Lupus Erythematosus: Relationship between Current Use and Cardiovascular Risk Factors. 2008 , 1, 23-28		8
165	Are there models for predicting accelerated atherogenesis in systemic lupus erythematosus?. 2008 , 4, 450-1		1
164	Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors. <i>Arthritis Research and Therapy</i> , 2008 , 10, R49	5.7	48
163	[Hydroxychloroquine and systemic lupus: a reappraisal]. 2008 , 29, 735-7		9
162	Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain. <i>Lupus</i> , 2008 , 17, 849-59	2.6	62
161	EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. 2008 , 67, 195-205		493
160	Hypertension in rheumatoid arthritis. 2008 , 47, 1286-98		197
159	Therapy Insight: cardiovascular disease in pediatric systemic lupus erythematosus. 2008 , 4, 258-65		16
158	Hydroxychloroquine: the cornerstone of lupus therapy. <i>Lupus</i> , 2008 , 17, 271-3	2.6	51
157	Arterial events in persons with dermatomyositis and polymyositis. 2009 , 36, 1943-6		50
156	Changes in lipid profile between flare and remission of patients with systemic lupus erythematosus: a prospective study. 2009 , 36, 1639-45		9
155	Poor outcomes after acute myocardial infarction in systemic lupus erythematosus. 2009 , 36, 570-5		33
154	Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort. 2009 , 48, 817-22		80
153	Drugs Used in the Treatment of Rheumatoid Arthritis: Relationship between Current Use and Cardiovascular Risk Factors. 2009 , 2, 34-40		54
152	Cardiovascular risk assessment and treatment in systemic lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009 , 23, 481-94	5.3	26
151	Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. 2009 , 60, 1496-507		109
150	Subclinical atherosclerosis and endothelial dysfunction in young South-Asian patients with systemic lupus erythematosus. 2009 , 28, 1259-65		23

149	Atherosclerosis risk factors in systemic lupus erythematosus. 2009 , 11, 241-7		18
148	Epidemiology of atherosclerosis in systemic lupus erythematosus. 2009 , 11, 248-54		32
147	High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. 2010 , 116, 22-6		62
146	Lupus registries: evolution and challenges. 2010 , 39, 224-45		16
145	Effect of medication on microvascular vasodilatation in patients with systemic lupus erythematosus. 2010 , 107, 919-24		16
144	Short communication: preferential concentration of hydroxychloroquine in adenoid tissue of HIV-infected subjects. 2010 , 26, 339-42		12
143	Contemporary treatment of systemic lupus erythematosus: an update for clinicians. 2010 , 1, 163-75		39
142	Genetically determined serum levels of mannose-binding lectin correlate negatively with common carotid intima-media thickness in systemic lupus erythematosus. 2010 , 37, 1815-21		13
141	A new role for antimalarials in systemic lupus erythematosus treatment. 2010 , 5, 299-312		1
140	Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. 2010 , 69, 20-8		645
139	Variability over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus: a longitudinal cohort study. <i>Arthritis Research and Therapy</i> , 2010 , 12, R125	5-7	20
138	Prevalence and burden of pediatric-onset systemic lupus erythematosus. 2010 , 6, 538-46		182
137	The role of antimalarial agents in the treatment of SLE and lupus nephritis. 2011 , 7, 718-29		166
136	Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study. <i>Arthritis Research and Therapy</i> , 2011 , 13, R156	5-7	61
135	Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. <i>Arthritis Research and Therapy</i> , 2011 , 13, R131	5-7	169
134	Clinical research in systemic lupus erythematosus: immediate relevance to clinical practice. <i>International Journal of Rheumatic Diseases</i> , 2011 , 14, 1-5	2-3	5
133	Antimalarials and SLE. 2011 , 1061-1081		0
132	[Metabolic syndrome in inflammatory rheumatic diseases]. 2006 , 58, 169-76		2

131	Prevalence of LDL atherogenic phenotype in patients with systemic lupus erythematosus. 2011 , 7, 75-80	19
130	Dyslipidaemia in patients with lupus nephritis. 2011 , 16, 511-7	26
129	Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients. 2011 , 63, 530-4	100
128	Corticosteroid and Nonsteroidal Anti-Inflammatory Drug use in Systemic Lupus Erythematosus. 2011 , 1045-1060	
127	Prevalence of and factors associated with hypertension in young and old women with systemic lupus erythematosus. 2011 , 38, 1026-32	71
126	Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. 2012 , 176, 708-19	192
125	Accelerated cardiovascular disease in patients with lupus: a review. 2012 , 25, 28-32	1
124	Cardio-renal syndrome type 5: epidemiology, pathophysiology, and treatment. 2012 , 32, 49-56	21
123	Riesgo cardiovascular en el lupus eritematoso sistémico: factores implicados y métodos para su valoración. 2012 , 13, 95-102	1
122	Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. <i>Lupus</i> , 2012 , 21, 1178-82	2.6 87
121	Utilizing registries in systemic lupus erythematosus clinical research. 2012 , 8, 353-60	10
120	Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects. 2012 , 42, 968-78	73
119	Glucocorticoid use and abuse in SLE. 2012 , 51, 1145-53	138
118	Inflammation and Atherosclerosis. 2012 ,	3
117	Cardiovascular Involvement in Systemic Lupus Erythematosus. 2012 ,	1
116	Dieta e aspectos nutricionais no lúpus eritematoso sistémico. 2012 , 52, 395-408	18
115	Comparison of alternative models for linking drug exposure with adverse effects. 2012 , 31, 1014-30	50
114	New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. 2012 , 8, 522-33	145

113	Premature coronary heart disease in systemic lupus erythematosus: what risk factors do we understand?. <i>Lupus</i> , 2013 , 22, 1243-50	2.6	36
112	Systemic lupus erythematosus. 2013 , 159, ITC4-1		18
111	Minimising steroids in lupus nephritis--will B cell depletion pave the way?. <i>Lupus</i> , 2013 , 22, 390-9	2.6	24
110	Is there an effective treatment for late-onset systemic lupus erythematosus?. 2013 , 9, 437-450		
109	The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. 2013 , 43, 77-95		212
108	Cardiovascular risk in pediatric-onset rheumatological diseases. <i>Arthritis Research and Therapy</i> , 2013 , 15, 212	5.7	34
107	Ambulatory blood pressure and subclinical cardiovascular disease in patients with juvenile-onset systemic lupus erythematosus. 2013 , 28, 305-13		21
106	The early cardiovascular changes in pediatric patients with systemic lupus erythematosus. 2013 , 28, 471-6		26
105	Multifaceted effects of hydroxychloroquine in human disease. 2013 , 43, 264-72		88
104	The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. 2013 , 40, 831-41		79
103	Assessment of coronary risk based on cumulative exposure to lipids in systemic lupus erythematosus. 2013 , 40, 2006-14		4
102	A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus. 2013 , 43, 547-53		15
101	The biological and clinical activity of anti-malarial drugs in autoimmune disorders. 2013 , 9, 45-62		27
100	Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial. 2014 , 66, 1246-51		45
99	Antipalúdicos en dermatologá: mecanismo de acci3n, indicaciones y efectos secundarios. 2014 , 105, 243-252		27
98	Cardiac manifestations of systemic lupus erythematosus. 2014 , 40, 51-60		81
97	Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease. 2014 , 65, 177-85		21
96	The effects of rituximab on the lipid profile of patients with active systemic lupus erythematosus: results from a nationwide cohort in Spain (LESIMAB). <i>Lupus</i> , 2014 , 23, 1014-22	2.6	8

95	A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role. 2014 , 5, 77-85		52
94	[Atherosclerosis in systemic lupus erythematosus]. 2014 , 43, 1034-47		9
93	Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus. 2014 , 47, 67-76		43
92	Atherosclerotic plaques occur in absence of intima-media thickening in both systemic sclerosis and systemic lupus erythematosus: a duplexsonography study of carotid and femoral arteries and follow-up for cardiovascular events. <i>Arthritis Research and Therapy</i> , 2014 , 16, R54	5.7	35
91	Antimalarials in dermatology: mechanism of action, indications, and side effects. 2014 , 105, 243-52		14
90	Hydroxychloroquine: a multifaceted treatment in lupus. 2014 , 43, e167-80		101
89	Prevention and management of co-morbidities in SLE. 2014 , 43, e187-95		21
88	Cardiometabolic and immune factors associated with increased common carotid artery intima-media thickness and cardiovascular disease in patients with systemic lupus erythematosus. 2014 , 24, 751-9		34
87	Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2015 , 17, 277	5.7	46
86	Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. <i>Arthritis and Rheumatology</i> , 2015 , 67, 2176-84	9.5	87
85	Systemic Corticosteroids for Inflammatory Disorders in Pediatrics. 2015 ,		
84	Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2015 , 14, 358-62	13.6	84
83	Systemic lupus erythematosus: review of synthetic drugs. 2015 , 16, 2793-806		14
82	Treatment of severe lupus nephritis: the new horizon. 2015 , 11, 46-61		67
81	Mechanisms of Inflammatory Atherosclerosis in Rheumatoid Arthritis. 2016 , 12, 35-46		12
80	Current and emerging treatment options in the management of lupus. 2016 , 5, 9-20		28
79	Hydroxychloroquine in Systemic Lupus Erythematosus: Comment on the Article by Muangchan et al. 2016 , 68, 1052-3		0
78	Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial. 2017 , 3, 92-97		22

77	Cardiac Involvement in Systemic Lupus Erythematosus. 2017 , 265-293		
76	Cardiac Effects of Antirheumatic Drugs. 2017 , 14, 489-529		
75	Dyslipidemia in systemic lupus erythematosus. <i>Immunologic Research</i> , 2017 , 65, 543-550	4.3	52
74	A rare case of acute myocardial infarction with a non-specific symptom in a young female with systemic lupus erythematosus. <i>Journal of Cardiology Cases</i> , 2017 , 16, 56-61	0.6	0
73	Cardiovascular disease in systemic lupus erythematosus: A comprehensive update. <i>Journal of Autoimmunity</i> , 2017 , 82, 1-12	15.5	93
72	Atherosclerosis in systemic lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017 , 31, 364-372	5.3	34
71	Clinical significance of lipid profile in systemic lupus erythematosus patients: Relation to disease activity and therapeutic potential of drugs. <i>Egyptian Rheumatologist</i> , 2017 , 39, 93-98	1	7
70	Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. <i>Immunologic Research</i> , 2017 , 65, 17-24	4.3	58
69	Type-5 Cardiorenal Syndrome (CRS-5): An up to Date. <i>Nephrology @ Point of Care</i> , 2017 , 3, napoc.5000212.5		
68	Contribution of MTHFR gene variants in lupus related subclinical atherosclerosis. <i>Clinical Immunology</i> , 2018 , 193, 110-117	9	16
67	Non-traditional risk factors for atherosclerotic disease: A review for emergency physicians. <i>American Journal of Emergency Medicine</i> , 2018 , 36, 494-497	2.9	16
66	Tuftsinn-phosphorylcholine (TPC) equally effective to methylprednisolone in ameliorating lupus nephritis in a mice model. <i>Clinical and Experimental Immunology</i> , 2018 , 193, 160-166	6.2	9
65	Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort. <i>Lupus</i> , 2018 , 27, 722-727	2.6	38
64	Understanding systemic lupus erythematosus patientsTdesired outcomes and their perceptions of the risks and benefits of using corticosteroids. <i>Lupus</i> , 2018 , 27, 475-483	2.6	5
63	Favorable effects of hydroxychloroquine on serum low density lipid in patients with systemic lupus erythematosus: A systematic review and meta-analysis. <i>International Journal of Rheumatic Diseases</i> , 2018 , 21, 84-92	2.3	21
62	Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus. <i>Mediators of Inflammation</i> , 2018 , 2018, 3424136	4.3	35
61	Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis. <i>Drug Design, Development and Therapy</i> , 2018 , 12, 1685-1695	4.4	53
60	Systemic Lupus Erythematosus for Primary Care. <i>Primary Care - Clinics in Office Practice</i> , 2018 , 45, 257-270.2		1

59	Incidence of cardiovascular risk factors in female patients with systemic lupus erythematosus: a 3-year follow-up cohort. <i>Lupus</i> , 2018 , 27, 1790-1798	2.6	5
58	NMR-Based Serum Metabolomics Reveals Reprogramming of Lipid Dysregulation Following Cyclophosphamide-Based Induction Therapy in Lupus Nephritis. <i>Journal of Proteome Research</i> , 2018 , 17, 2440-2448	5.6	12
57	Cardiorenal Syndrome Type 5. 2019 , 704-711.e2		
56	Automated Segmentation Measurements of the Outer Nuclear Layer in Determining Cases of Hydroxychloroquine Toxicity: A Retrospective Study. <i>Journal of Vitreoretinal Diseases</i> , 2019 , 3, 135-144	0.7	2
55	Hydroxychloroquine for prevention of recurrent miscarriage: study protocol for a multicentre randomised placebo-controlled trial BBQ study. <i>BMJ Open</i> , 2019 , 9, e025649	3	12
54	Microvascular heart involvement in systemic autoimmune diseases: The purinergic pathway and therapeutic insights from the biology of the diseases. <i>Autoimmunity Reviews</i> , 2019 , 18, 317-324	13.6	5
53	Development of a systemic lupus erythematosus cardiovascular risk equation. <i>Lupus Science and Medicine</i> , 2019 , 6, e000346	4.6	24
52	Systemic lupus erythematosus: Diagnosis and clinical management. <i>Journal of Autoimmunity</i> , 2019 , 96, 1-13	15.5	175
51	Systemic lupus erythematosus and menopause. <i>Climacteric</i> , 2020 , 23, 109-115	3.1	6
50	The Effects of Chloroquine and Hydroxychloroquine on ACE2-Related Coronavirus Pathology and the Cardiovascular System: An Evidence-Based Review. <i>Function</i> , 2020 , 1,	6.1	10
49	Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study. <i>Arthritis Research and Therapy</i> , 2020 , 22, 191	5.7	8
48	Hydroxychloroquine is protective to the heart, not harmful: a systematic review. <i>New Microbes and New Infections</i> , 2020 , 37, 100747	4.1	11
47	The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?. <i>Pharmacological Research</i> , 2020 , 158, 104904	10.2	72
46	Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. <i>Advances in Rheumatology</i> , 2020 , 60, 32	3	24
45	Antimalarial Agents. 2021 , 234-244.e4		1
44	Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2021 , 73, 997-1004	9.5	7
43	Accelerated atherosclerosis and cardiovascular disease in systemic lupus erythematosus. <i>Revista Colombiana De Reumatología</i> , 2021 , 28, 21-30	0.2	1
42	Analytical Methodologies for Determination of Hydroxychloroquine and Its Metabolites in Pharmaceutical, Biological and Environmental Samples. <i>Current Pharmaceutical Analysis</i> , 2021 , 17,	0.6	0

41	Coronary Microvascular Dysfunction in Systemic Lupus Erythematosus. <i>Journal of the American Heart Association</i> , 2021 , 10, e018555	6	4
40	Autoimmune-mediated renal disease and hypertension. <i>Clinical Science</i> , 2021 , 135, 2165-2196	6.5	1
39	Effects of Hydroxychloroquine on endothelial function in elderly with sleep apnea (HOLD): study protocol for a randomized clinical trial. <i>Trials</i> , 2021 , 22, 638	2.8	0
38	Assessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis. <i>International Journal of Women's Dermatology</i> , 2021 , 7, 560-575	2	1
37	The impact of antimalarial agents on traditional and non-traditional subclinical atherosclerosis biomarkers in systemic lupus erythematosus: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2021 , 20, 102887	13.6	0
36	Antimalarial drugs (and lupus). 2021 , 601-609		
35	Standard therapeutic regimens for vasculitis. 2001 , 21-40		1
34	Systemic Lupus Erythematosus. 2017 , 145-163		2
33	Anti-Inflammatory Therapeutic Approaches. 2012 , 513-528		1
32	Cardiovascular Morbidity in the Hopkins Lupus Cohort. 2001 , 249-254		2
31	Atherosclerosis in Systemic Lupus Erythematosus. 2001 , 255-265		1
30	Cardiac and Pulmonary Manifestations in the Antiphospholipid Syndrome. 2002 , 169-188		2
29	Antimalarial drugs in systemic lupus erythematosus: use in pregnancy. <i>Drug Safety</i> , 2001 , 24, 1055-63	5.1	34
28	The effect of hydroxychloroquine on glucose control and insulin resistance in the prediabetes condition. <i>Advanced Biomedical Research</i> , 2016 , 5, 145	1.2	15
27	Myocardial revascularization in two patients associated with antiphospholipid syndrome: different pathogenic patterns and angiographic results. <i>Korean Journal of Thoracic and Cardiovascular Surgery</i> , 2011 , 44, 423-6	0.6	1
26	Dyslipoproteinemia and Premature Atherosclerosis in the Pediatric Rheumatic Disease. 2001 , 329-333		
25	Homocysteine and Vascular Disease in the Autoimmune Connective Tissue Diseases. 2001 ,		
24	What will treatment of autoimmune diseases entail in 2010?. 2002 , 187-192		

23	Inflammatory Diseases of the Coronary Artery. 2002 , 935-970		
22	ANTIMALARIALS AND IMMUNOSUPPRESSIVE THERAPIES. 2004 , 1273-1293		
21	Lipid Abnormalities in Children with Systemic Lupus Erythematosus (SLE). <i>AAP Grand Rounds</i> , 2006 , 16, 45-46	0.7	
20	Cardiac involvement in systemic lupus erythematosus. <i>Annales Universitatis Mariae Curie-Sklodowska Sectio D: Medicina</i> , 2008 , 63, 25-31		
19	Relationship between adverse drug reaction of oral corticosteroid therapy and background factors in systemic lupus erythematosus. <i>Juntendo Igaku</i> , 2010 , 56, 268-273	1	
18	Cardiovascular Risk and Prevention in Rheumatic Diseases. 2010 , 1200-1204.e2		
17	Atherosclerosis in the Rheumatic Diseases: Compounding the Age Risk. 2011 , 17-25		
16	Cardiac and Vascular Disease in SLE. 2012 , 107-114		
15	Corticosteroids in Pediatric-Onset SLE and Other Connective Tissue Diseases. 2015 , 95-103		
14	Metabolic Syndrome Post Liver Transplantation. 2015 , 218-229		
13	Cardiovascular damage during lupus in black African subjects. <i>Journal of Cardiology and Cardiovascular Medicine</i> , 031-034	0.1	
12	Antipalúdicos de síntesis en dermatología. <i>EMC - Dermatología</i> , 2020 , 54, 1-11	0.1	
11	Type-5 Cardiorenal Syndrome. 2021 , 111-124		0
10	Atherosclerotic vascular disease in systemic lupus erythematosus. <i>Journal of the National Medical Association</i> , 2002 , 94, 813-9	2.3	12
9	Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge.. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022 , 14, 1759720X211073001	3.8	5
8	Cardiovascular Implications of Immune Disorders in Women.. <i>Circulation Research</i> , 2022 , 130, 593-610	15.7	0
7	Hydroxychloroquine increased cholesterol transfer to high-density lipoprotein in systemic lupus erythematosus: A possible mechanism for the reversal of atherosclerosis in the disease.. <i>Lupus</i> , 2022 , 9612033221090127	2.6	0
6	Drug monitoring in systemic lupus erythematosus.. <i>Current Opinion in Pharmacology</i> , 2022 , 64, 102225	5.1	

- 5 Risco cardiovascular no lpus eritematoso sistmico. *Revista Paulista De Reumatologia*, **2015**, 13-19 0.1
- 4 Antimalarial agents. **2013**, 241-251.e3 3
- 3 Hydroxychloroquine Lowers the Risk for Diabetes Mellitus in Patients with Systemic. *Diabetes Epidemiology and Management*, **2022**, 100089
- 2 Atherosclerosis in Vietnamese patients with systemic sclerosis and its relation to disease and traditional risk factors. *Rheumatology Advances in Practice*, 1.1 1
- 1 Spontaneous coronary artery dissection and atherosclerosis in a young man with systemic lupus erythematosus: A case report and literature review. 9,